|
TMEM19 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.70419999999871E-05 |
| Normal-vs-Stage3 |
5.55111512312578E-16 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
4.460000E-02 |
| Stage1-vs-Stage3 |
6.307400E-01 |
| Stage1-vs-Stage4 |
3.098300E-03 |
| Stage2-vs-Stage3 |
3.076200E-02 |
| Stage2-vs-Stage4 |
5.157200E-04 |
| Stage3-vs-Stage4 |
2.975700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
2.26540000092257E-08 |
| Normal-vs-Asian |
1.90447657644199E-12 |
| Caucasian-vs-AfricanAmerican |
6.265400E-01 |
| Caucasian-vs-Asian |
8.276800E-01 |
| AfricanAmerican-vs-Asian |
4.939800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.55111512312578E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.171000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
3.56381590904675E-14 |
| Normal-vs-Age(61-80Yrs) |
1.82909243306995E-12 |
| Normal-vs-Age(81-100Yrs) |
2.682300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.365000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.586190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.434200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.105800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.803800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.405200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.263700E-02 |
| Classical-VS-Follicular |
8.040200E-03 |
| Classical-VS-Other |
6.686800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.000590E-03 |
| Tall-VS-Other |
7.528600E-01 |
| Tall-VS-Normal |
2.00106597958438E-12 |
| Follicular-VS-Other |
2.502400E-01 |
| Follicular-VS-Normal |
1.51079999954895E-07 |
| Other-VS-Normal |
5.66530000000176E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.56807899998057E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
5.23239999994374E-07 |
|
|
